Cargando…

Tumor-Intrinsic or Drug-Induced Immunogenicity Dictates the Therapeutic Success of the PD1/PDL Axis Blockade

Immunotherapy with immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment providing unprecedented clinical benefits. However, many patients do not respond to ICIs as monotherapy or develop resistance. Combining ICI-based immunotherapy with chemotherapy is a promising strategy to inc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rossi, Alessandra, Lucarini, Valeria, Macchia, Iole, Sestili, Paola, Buccione, Carla, Donati, Simona, Ciccolella, Maria, Sistigu, Antonella, D’Urso, Maria Teresa, Pacca, Anna Maria, Cardarelli, Enrico, Mattei, Fabrizio, Proietti, Enrico, Schiavoni, Giovanna, Bracci, Laura
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226952/ https://www.ncbi.nlm.nih.gov/pubmed/32290265 http://dx.doi.org/10.3390/cells9040940

Ejemplares similares

Anticancer Effects of Sublingual Type I IFN in Combination with Chemotherapy in Implantable and Spontaneous Tumor Models
por: Ciccolella, Maria, et al.
Publicado: (2021)

Chemo-immunotherapy induces tumor regression in a mouse model of spontaneous mammary carcinogenesis
por: Aricò, Eleonora, et al.
Publicado: (2016)

IL-33 Promotes CD11b/CD18-Mediated Adhesion of Eosinophils to Cancer Cells and Synapse-Polarized Degranulation Leading to Tumor Cell Killing
por: Andreone, Sara, et al.
Publicado: (2019)

Immune Monitoring in Cancer Vaccine Clinical Trials: Critical Issues of Functional Flow Cytometry-Based Assays
por: Macchia, Iole, et al.
Publicado: (2013)

Blood immune cells as potential biomarkers predicting relapse-free survival of stage III/IV resected melanoma patients treated with peptide-based vaccination and interferon-alpha
por: Moschella, Federica, et al.
Publicado: (2023)

The Pleiotropic Immunomodulatory Functions of IL-33 and Its Implications in Tumor Immunity
por: Afferni, Claudia, et al.
Publicado: (2018)

Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy
por: Makuku, Rangarirai, et al.
Publicado: (2021)

Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma
por: Rozera, Carmela, et al.
Publicado: (2015)

PDL-1 Blockade Prevents T Cell Exhaustion, Inhibits Autophagy, and Promotes Clearance of Leishmania donovani
por: Habib, Samar, et al.
Publicado: (2018)

CD40- and 41BB-specific antibody fusion proteins with PDL1 blockade-restricted agonism
por: Medler, Juliane, et al.
Publicado: (2022)

Synthesis of Novel Peptide Dendrimers PDL-GB2 and PDL-G2
por: Yunzhu, Lin, et al.
Publicado: (2015)

Eosinophils as potential biomarkers in respiratory viral infections
por: Macchia, Iole, et al.
Publicado: (2023)

Antagonistic Inflammatory Phenotypes Dictate Tumor Fate and Response to Immune Checkpoint Blockade
por: Bonavita, Eduardo, et al.
Publicado: (2020)

Intertumoral Differences Dictate the Outcome of TGF-β Blockade on the Efficacy of Viro-Immunotherapy
por: Groeneveldt, Christianne, et al.
Publicado: (2023)

ICSBP Is Essential for the Development of Mouse Type I Interferon-producing Cells and for the Generation and Activation of CD8α(+) Dendritic Cells
por: Schiavoni, Giovanna, et al.
Publicado: (2002)

CSF1/CSF1R Axis Blockade Limits Mesothelioma and Enhances Efficiency of Anti-PDL1 Immunotherapy
por: Magkouta, Sophia Fotiou, et al.
Publicado: (2021)

Dragon Dictate 2.5
por: Langer, Maria
Publicado: (2012)

P53-regulated miR-320a targets PDL1 and is downregulated in malignant mesothelioma
por: Costa, Caterina, et al.
Publicado: (2020)

Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study
por: Sun, Yiting, et al.
Publicado: (2021)

Identification of PDL1-Related Biomarkers to Select Lung Adenocarcinoma Patients for PD1/PDL1 Inhibitors
por: Wu, Yanping, et al.
Publicado: (2020)

Correction: P53-regulated miR-320a targets PDL1 and is downregulated in malignant mesothelioma
por: Costa, Caterina, et al.
Publicado: (2020)

Identification of candidate genes and prognostic value analysis in patients with PDL1-positive and PDL1-negative lung adenocarcinoma
por: Qi, Xiaoguang, et al.
Publicado: (2020)

Hypoxia Dictates Metabolic Rewiring of Tumors: Implications for Chemoresistance
por: Belisario, Dimas Carolina, et al.
Publicado: (2020)

TIM-3 as a molecular switch for tumor escape from innate immunity
por: Mattei, Fabrizio, et al.
Publicado: (2013)

The Dictator
Publicado: (1906)

Combination therapy of chemokine receptor inhibition plus PDL-1 blockade potentiates anti-tumor effects in a murine model of breast cancer
por: Jung, Heiyoun, et al.
Publicado: (2015)

Expanded human NK cells from lung cancer patients sensitize patients’ PDL1−negative tumors to PD1-blockade therapy
por: Poznanski, Sophie M, et al.
Publicado: (2021)

Genetics of classical Hodgkin Lymphoma
por: Schiavoni, Gianluca, et al.
Publicado: (2018)

Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study
por: Urbani, Francesca, et al.
Publicado: (2020)

Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves antitumor immunity and renders anti-PDL1-resistant tumors anti-PDL1-sensitive through NK cell effects
por: Bai, Haiyan, et al.
Publicado: (2023)

Retroviral Replicating Vector Delivery of miR-PDL1 Inhibits Immune Checkpoint PDL1 and Enhances Immune Responses In Vitro
por: Lin, Amy H., et al.
Publicado: (2017)

PDL1 shapes the classical Hodgkin lymphoma microenvironment without inducing T-cell exhaustion
por: Taylor, Joseph G., et al.
Publicado: (2022)

PDL1 Regulation by p53 via miR-34
por: Cortez, Maria Angelica, et al.
Publicado: (2015)

Prognostic value of PDL1 expression in pancreatic cancer
por: Birnbaum, David J., et al.
Publicado: (2016)

Chronic Isolation Stress Affects Central Neuroendocrine Signaling Leading to a Metabolically Active Microenvironment in a Mouse Model of Breast Cancer
por: Berry, Alessandra, et al.
Publicado: (2021)

PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy
por: Sponaas, Anne-Marit, et al.
Publicado: (2015)

Anlotinib Benefits the αPDL1 Immunotherapy by Activating ROS/JNK/AP-1 Pathway to Upregulate PDL1 Expression in Colorectal Cancer
por: Luo, Bixian, et al.
Publicado: (2022)

DAMPE: A gamma and cosmic ray observatory in space
por: D'Urso, D
Publicado: (2017)

A transcribed enhancer dictates mesendoderm specification in pluripotency
por: Alexanian, Michael, et al.
Publicado: (2017)

Grammar dictation /
por: Wajnryb, Ruth
Publicado: (1990)

Cannot write session to /tmp/vufind_sessions/sess_5ijmhfq6h5on9vel395q3iikg5